Kadmon Holdings LLC (KDMN)

NASDAQ
9.500
0.000(0.00%)
  • Volume:
    0
  • Day's Range:
    9.480 - 9.500
  • 52 wk Range:
    3.450 - 9.500
Trading near 52-week High

Kadmons has hit the highest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

KDMN Overview

Prev. Close
9.5
Day's Range
9.48-9.5
Revenue
760K
Open
9.49
52 wk Range
3.45-9.5
EPS
-0.71
Volume
0
Market Cap
1.7B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
10,424,582
P/E Ratio
-
Beta
1.21
1-Year Change
6.86%
Shares Outstanding
178,521,071
Next Earnings Date
-
What is your sentiment on Kadmons?
or
Market is currently closed. Voting is open during market hours.

Kadmon Holdings LLC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Kadmon Holdings LLC Analysis

Kadmon Holdings LLC Company Profile

Kadmon Holdings LLC Company Profile

Employees
127

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson’s disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. As of November 9, 2021, Kadmon Holdings, Inc. operates as a subsidiary of Sanofi.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary
  • How do I buy?
    0
    • buy at 8.67 and sell for 9.50. thats easy money
      1
      • It's good stock!andAIRI is next pumping stock
        0
        • Full FDA Approval on this today
          0
          • PT 25$!!!
            0